secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-06-30T20:05:15+00:00
Accession:  0001193125-26-290473
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo awarded $1.5M non-dilutive grant from Andy Hill CARE Fund for APVO451 IND-enabling studies
--------------------------------------------------------------------------------

- Grant of $1,499,951 from Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling studies for APVO451, a trispecific antibody targeting nectin-4, CD40, and CD3 for solid tumors.
- Funding is non-dilutive and on a reimbursement basis; project period through June 2028, subject to milestones and matching contributions.
- APVO451 advancing toward development candidate selection by year-end 2026 and IND-enabling studies in Q1 2027.
- Grant provides external validation of APVO451's trispecific design and supports Aptevo's solid tumor immunotherapy efforts.
- Aptevo retains IP ownership; grant includes customary terms including acknowledgment and commercialization commitments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526290473/0001193125-26-290473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526290473/apvo-20260629.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-290473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer